Updated: Mar 14, 2008
Facial fractures occur for a variety of reasons related to sports participation: contact between players (eg, a head, fist, elbow); contact with equipment (eg, balls, pucks, handlebars); or contact with the environment, obstacles, or a playing surface (eg, wrestling mat, gymnastic equipment, goalposts, trees). Although most sports-related facial injuries are minor, the potential for serious damage exists. A physician examining these injuries must rapidly assess the patient in a consistent and methodical manner, allowing for prompt diagnosis and appropriate treatment, while considering the physical demands of the sport, as well as the athlete's return to play.
Facial fractures may be associated with head and cervical spine injuries.1,2 A review by Boden et al of catastrophic injuries associated with high school and college baseball demonstrated 1.95 direct catastrophic injuries annually, including severe head injuries, cervical injuries, and associated facial fractures.2
Fractures of the facial bones require a significant amount of force. The physician must take into account the mechanism of the injury as well as the physical examination findings when assessing the patient.
Forces that are required to produce a fracture of the facial bones are as follows:
For excellent patient education resources, visit eMedicine's Back, Ribs, Neck, and Head Center; Breaks, Fractures, and Dislocations Center; Sports Injury Center; Eye and Vision Center; and Teeth and Mouth Center.
Also, see eMedicine's patient education articles Facial Fracture, Broken Nose, Broken Jaw, Concussion, Black Eye, and Broken or Knocked-out Teeth.
Related eMedicine topics:
Cervical Spine Sprain/Strain Injuries
Facial Trauma, Maxillary and Le Fort Fractures
Facial Trauma, Sports-Related Injuries
Related Medscape topics:
Resource Center Adolescent Medicine
Resource Center Exercise and Sports Medicine
Resource Center Trauma
Schulz noted that athletic injuries account for 11% of all facial fractures, and that facial injuries occur in 2% of all athletes.3
In another report, Laskin stated that 250,000 individuals, many of whom were children, experience facial trauma while engaged in athletic activities.4 Additionally, more than 100,000 sport-related injuries could be prevented by wearing appropriate head and face protection.
A review of facial fractures sustained by athletes during sports participation noted that in the medical literature, sporting activities account for 3-29% of facial injuries and 10-42% of all facial fractures.5 Tanaka and colleagues showed that 10.4% of all maxillofacial fractures are related to sports.6
Nearly 75% of facial fractures occur in the mandible, zygoma, and nose.7 Sports participation is the most common cause of mandibular fractures (31.5%), followed closely by motor vehicle accidents (27.2%). A study of facial fractures sustained during recreational baseball and softball demonstrated that the zygoma or zygomatic arch was the most common fracture subtype, followed by temporoparietal skull fractures and orbital blow-out fractures.8 A number of studies in the medical literature, however, indicate that the nasal bones are the most commonly fractured bones in the face, but because many of these patients do not seek medical treatment or the injuries are managed in the outpatient setting, the statistics may not reflect this trend.1 It is likely that the nasal bones are more commonly fractured because of the lesser degree of force that is required to fracture the bone.9
Fractures of the orbit occur more commonly in young adult and adolescent males: the mean age for adult males is 32 years; the mean age for children, 12.5 years, and the majority of orbital fractures occur in boys. In addition to sports-related injuries, injuries sustained in motor vehicle collisions, assaults, and occupational injuries account for the majority of orbital fractures.10
Related eMedicine topics:
Facial Trauma, Maxillary and Le Fort Fractures
Orbit Anatomy
Related Medscape topics:
Facial Fractures May Be Safely Repaired in War Zones
Neuroimaging in Neuroophthalmology
In general, facial fractures in athletic activities result from direct trauma over a small surface area. Sports that present a higher risk are those that involve small objects that are propelled at high velocity, such as baseball, softball, hockey, lacrosse, jai alai, and racquetball. Athletes who participate in sports with high levels of physical contact and collision are at risk as well; these sports include football, basketball, rugby, hockey, martial arts, and boxing.
Many of these sports have safety measures to limit the incidence of facial injuries, and attention should be paid to the rules of use. Racquetball players should always play with goggles to limit orbital blow-out injuries. In hockey, face guards with helmets are required in lower levels of play but not at the professional level. High school football players should all have mouthpieces fitted for them, and mouthpieces should be worn in place before every play.
An athlete's vision should be checked as part of a preparticipation physical examination yearly. Visual risk factors include a corrected visual acuity of 20/40 or less or spectacle correction greater than 6 diopters (D). These athletes need an ophthalmologist's evaluation before competing in sports.
A one-eyed athlete is defined as one with a visual acuity in one eye of 20/200 or less. These athletes may be able to participate with proper protection, and an ophthalmologist's evaluation is essential.
Related eMedicine topic:
Sports Physicals
Related Medscape topics:
Resource Center Adolescent Medicine
Resource Center Exercise and Sports Medicine
Injuries to the head and neck frequently involve the airway or major vessels. The initial assessment, therefore, should begin with airway, breathing, and circulation (ABCs).
First, protect the airway by removing any foreign bodies and by placing the patient in a sitting position or on the side to facilitate expectoration of blood. If severe maxillofacial trauma is present, the athlete is at risk for airway obstruction because of a lack of tongue support from the mandibular structures. Consider placing an oral airway or, if necessary, performing endotracheal intubation. Second, assess the athlete for breathing and circulation. Lastly, evaluate the cervical spine. In the literature, cervical spine injuries have been shown to be present in 1-4% of patients with facial fractures. Because of the force necessary to fracture the facial bones, one should consider the cervical spine is fractured until proven otherwise, and cervical spine immobilization should be maintained.
Following initial stabilization of the ABCs, the examiner should proceed with the history and physical examination. The patient should be questioned regarding the mechanism of the injury, the presence of numbness or pain over any parts of the face, and visual disturbances. Specific questions regarding specific fractures of the face include the following:
Related eMedicine topics:
Cervical Spine Sprain/Strain Injuries
Facial Trauma, Maxillary and Le Fort Fractures
Facial Trauma, Sports-Related Injuries
Related Medscape topics:
Resource Center Adolescent Medicine
Resource Center Exercise and Sports Medicine
Resource Center Pain Management: Pharmacologic Approaches
Resource Center Resuscitation
The physical examination should be performed in a methodic, sequential manner. One approach organizes the examination from inside out and bottom up and involves inspection, palpation, and sensory and motor testing.
Examine the oral pharynx for lacerations, tooth fragments, or other foreign bodies. Look closely at the dentition to assess for tooth avulsion or tooth mobility, which can indicate underlying skeletal fractures. Then, carefully evaluate each region of the face, including the mandibular, maxillary, zygomal, nasal, orbital, and frontal bones.
Any areas of obvious trauma, such as a laceration, swelling, depression, or ecchymosis, should be examined more closely. Evaluate the mandible for trismus and mobility. The mid face should be assessed for stability and depression of the bones.
After inspection and palpation, test the motor and sensory function of the facial nerves and muscles. Hypoesthesia in the region of the infraorbital or supraorbital nerve may suggest an orbital fracture, whereas decreased sensation of the chin may result from inferior alveolar nerve compression from a mandibular fracture. Trismus, spasm of the muscles of the jaw, which results in the inability to open and close the mouth, can be secondary to mandibular or zygomatic fractures.
Any fluid from the nose should be inspected for possible CSF rhinorrhea, indicating disruption of the anterior cranial base. Lastly, examine the eyes, including the pupils, extraocular movements, visual acuity, and, if clinically indicated, intraocular pressure and corneal fluorescein. Findings for specific fractures include the following:
Cervical Spine Acute Bony Injuries
Cervical Spine Sprain/Strain Injuries
Concussion
Facial Soft Tissue Injuries
Nasal Fracture
Basilar skull fracture
Closed head injury
Corneal abrasion /laceration
Dental fracture/avulsion
Globe rupture
Nasal septal hematoma
Related Medscape topics:
Resource Center Sepsis
Resource Center Wound Management
Once a fracture has been identified, an appropriate surgeon or specialist (ie, plastic surgeon; ophthalmologist; ear, nose, and throat specialist; oral-maxillofacial surgeon; or neurosurgeon) provides the definitive care.
The goals of pharmacotherapy are to reduce morbidity and prevent complications.
Pain control is essential to quality patient care. Analgesics ensure patient comfort and have sedating properties, which are beneficial for patients who have sustained injuries.
Related Medscape topics:
Resource Center Pain Management: Advanced Approaches to Chronic Pain Management
Resource Center Pain Management: Pharmacologic Approaches
DOC for patients with mild to moderate pain. Inhibits inflammatory reactions and pain by decreasing prostaglandin synthesis.
400 mg PO q4h or 800 mg PO q8h; not to exceed 2400 mg qd
4-10 mg/kg PO q6-8h prn; not to exceed 50 mg/kg/d
Coadministration with aspirin increases the risk of inducing serious NSAID-related adverse effects; probenecid may increase the concentrations and, possibly, the toxicity of NSAIDs; may decrease the effect of hydralazine, captopril, and beta-blockers; may decrease the diuretic effects of furosemide and thiazides; may increase PT duration when taking anticoagulants (instruct patients to watch for signs of bleeding); may increase the risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently
Documented hypersensitivity; aspirin/NSAID-induced asthma; third trimester of pregnancy
B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus
Caution in patients with congestive heart failure, nasal polyps, hypertension, and decreased renal and hepatic function, and in elderly patients; caution in the presence of coagulation abnormalities or during anticoagulant therapy
DOC for pain in patients with a documented hypersensitivity to aspirin or NSAIDs, with upper GI disease, or who are taking PO anticoagulants.
325-1000 mg PO/PR q4-6h; not to exceed 4 g/d
10-15 mg/kg PO/PR q6-8h prn; not to exceed (if >12 y) 4 g/d
Alcohol, barbiturates, carbamazepine, INH, and phenytoin increase the risk of hepatotoxicity; rifampin decreases acetaminophen efficacy; acetaminophen doses >2 g/d may potentiate the warfarin effect and increase INR
Documented hypersensitivity; known G6PD
B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
Hepatotoxicity is possible in people with long-term alcoholism following various dose levels; severe or recurrent pain or high or continued fever may indicate a serious illness; acetaminophen is contained in many OTC products, and combined use with these products may result in cumulative acetaminophen doses that exceed the recommended maximum dose
Drug combination indicated for moderate to severe pain.
1-2 tab PO q4-6h prn; not to exceed 8 tab/d
500/7.5 per 15 mL, 0.6 mg/kg/d PO divided q6-8h; not to exceed 1.25 mg/dose if <2 y, 5 mg/dose if 2-12 y, 10 mg/dose if >12 y
Alcohol and INH increase the risk of hepatotoxicity; anticholinergics and antidiarrheals combination increase the risk of severe constipation; CNS depressants increase the risk of CNS depression; MAOIs increase the risk of severe hypertension; TCAs in combination increases the concentration of both drugs
Documented hypersensitivity; depressed respiratory function; increased ICP; acute abdominal pain; pseudomembranous colitis; toxin-related diarrhea; impaired liver function
C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
The tablets contain metabisulfite, which may cause hypersensitivity; caution in patients who are dependent on opiates because this substitution may result in acute opiate withdrawal symptoms; caution in the presence of severe renal or hepatic dysfunction
Drug combination indicated for the relief of moderate to severe pain.
1 tab or cap PO q6h
Not established
Phenothiazines may decrease the analgesic effects; conversely, toxicity increases when administered concurrently with CNS depressants or tricyclic antidepressants; may also potentiate the anticoagulant effects of warfarin
Documented hypersensitivity; liver damage; hypoprothrombinemia; vitamin K deficiency; bleeding disorders; asthma; use in children who have the flu and are <16 y (due to the association of aspirin with Reye syndrome)
D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus
Duration of action may increase in elderly patients; caution in the presence of renal or liver impairment, peptic ulcer disease, and erosive gastritis
Inhibits prostaglandin synthesis by decreasing the activity of the enzyme cyclooxygenase, which results in decreased formation of prostaglandin precursors.
30 mg IV/IM q6h; not to exceed 120 mg/d
10 mg PO q4-6h; not to exceed 40 mg/d
Combined duration of PO/IV/IM not to exceed 5 d
Not established
Coadministration with aspirin increases the risk of inducing serious NSAID-related adverse effects; probenecid may increase the concentrations and, possibly, the toxicity of NSAIDs; may decrease the effect of hydralazine, captopril, and beta-blockers; may decrease the diuretic effects of furosemide and thiazides; may increase PT duration when taking anticoagulants (instruct patients to watch for signs of bleeding); may increase the risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently
Documented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency; high risk of bleeding; administration into CNS
C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus
Acute renal insufficiency, hyperkalemia, hyponatremia, interstitial nephritis, and renal papillary necrosis may occur; increases the risk of acute renal failure in patients with preexisting renal disease or compromised renal perfusion; low WBC counts (rare) usually return to normal during ongoing therapy; discontinue therapy if persistent leukopenia, granulocytopenia, or thrombocytopenia occurs
DOC for analgesia because of its reliable and predictable effects, safety profile, and ease of reversibility with naloxone.
Various IV doses are used; commonly titrated until desired effect is obtained.
10 mg IM/SC q4h prn
Alternatively, 10-30 mg PO q4h or 10-20 mg PR q4h
0.2-0.5 mg/kg PO/PR q4-6h
Alternatively, 0.1-0.2 mg/kg IV/IM/SC q2-4h; not to exceed 15 mg/dose
Anticholinergics increase the risk of severe constipation; buprenorphine blocks the effects of morphine; precipitates withdrawal; cimetidine increases the effects of morphine; CNS depressants increase the risk of CNS depression; MAOIs combination increases the risk of hypotension and respiratory depression; rifampin decreases morphine concentrations; morphine may increase the serum levels of zidovudine
Documented hypersensitivity; hypotension; potentially compromised airway where establishing rapid airway control would be difficult
C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
Caution in patients with hypotension, respiratory depression, nausea, emesis, constipation, urinary retention, atrial flutter, and other supraventricular tachycardias; has vagolytic action and may increase the ventricular response rate
Antiemetics are useful in the treatment of symptomatic nausea.
Anti-dopaminergic agent that is effective in treating emesis. Blocks postsynaptic mesolimbic dopaminergic receptors in the brain and reduces stimuli to the brainstem reticular system.
12.5-25 mg PO/IM q4-6h prn
<2 years: Contraindicated
0.25-1 mg/kg PO/IM/PR q4-6h prn; not to exceed 25 mg/dose
May have additive effects when used concurrently with other CNS depressants or anticonvulsants; coadministration with epinephrine may cause hypotension
Documented hypersensitivity; glaucoma, narrow-angle; lactation; children younger than 2 y (incidences of death due to respiratory depression)
C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
Caution in the presence of impaired liver function, elderly patients, seizure disorder, and asthma
Selective 5-HT3-receptor antagonist that blocks serotonin both peripherally and centrally. Prevents nausea and vomiting associated with emetogenic cancer chemotherapy (eg, high-dose cisplatin) and complete body radiotherapy.
4 mg/dose IV
Alternatively, 0.15 mg/kg/dose PO
Not established
Although cytochrome P-450 inducers (eg, barbiturates, rifampin, carbamazepine, phenytoin) can potentially change the half-life and clearance of ondansetron, a dosage adjustment is not usually required
Documented hypersensitivity
B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
Medication is to be administered for prevention of nausea and vomiting, not for rescue of nausea and vomiting
In fractures that involve or approximate the eye, visual acuity is the most important factor in return to play. Any unexplained loss of acuity needs a complete workup. The aforementioned 20/40 criteria to play still apply (see Sport-Specific Biomechanics). Any athlete returning to competition without complete bone healing needs adequate protection, such as a full face shield, modified batting helmets, extended hockey eye visors, or larger football face masks.
Athletes need to regain their confidence in returning to play. An athlete who has physically recovered may not be mentally recovered from the trauma of the injury and, thus, is at risk of further injury. This is often observed in baseball players hit in the face by a pitch or hit ball. Psychologic recovery from facial fractures can be assessed in controlled practice situations. A consultation with a sports psychologist may be necessary if difficulties linger.
Return-to-play recommendations are not affected after orofacial fractures.12 In a report by Laskin, the author observed that more than 100,000 sport-related injuries could be prevented annually by wearing appropriate head and face protection.4
Related Medscape topics:
Resource Center Adolescent Medicine
Resource Center Exercise and Sports Medicine
Resource Center Trauma
Adherence to the rules and guidelines established by the specific sports governing body is most important. Almost all eye injuries are preventable, but other fractures can and do occur in sports with high levels of physical contact. Visual acuity, protective gear, and adherence to the rules of the sport are the best ways to limit the risk of facial fractures.
Related Medscape topics:
Resource Center Medical Malpractice and Legal Issues
Resource Center Resuscitation
Resource Center Trauma
Costello BJ, Papadopoulos H, Ruiz R. Pediatric craniomaxillofacial trauma. Clin Pediatr Emerg Med. 2005;6(1):32-40.
Boden BP, Tacchetti R, Mueller FO. Catastrophic injuries in high school and college baseball players. Am J Sports Med. Jul-Aug 2004;32(5):1189-96. [Medline].
Schulz RC. Facial Injuries. 2nd ed. Chicago, Ill: Yearbook Medical Publishers, Inc; 1977.
Laskin DM. Protecting the faces of America. J Oral Maxillofac Surg. Apr 2000;58(4):363. [Medline].
Romeo SJ, Hawley CJ, Romeo MW, Romeo JP. Facial injuries in sports: a team physician's guide to diagnosis and treatment. Phys Sportsmed. Apr 2005;33(4):45-53. [Full Text].
Tanaka N, Hayashi S, Suzuki K, et al. [Clinical study of maxillofacial fractures sustained during sports and games] [Japanese]. Kokubyo Gakkai Zasshi. Sep 1992;59(3):571-7. [Medline].
Iida S, Kogo M, Sugiura T, Mima T, Matsuya T. Retrospective analysis of 1502 patients with facial fractures. Int J Oral Maxillofac Surg. Aug 2001;30(4):286-90. [Medline].
Bak MJ, Doerr TD. Craniomaxillofacial fractures during recreational baseball and softball. J Oral Maxillofac Surg. Oct 2004;62(10):1209-12. [Medline].
Reyes Mendez D, Lapointe A. Nasal trauma and fractures in children. UpToDate [serial online]. May 2007;Accessed September 14, 2007. Available at www.UpToDate.com.
Neuman MI, Bachur RG. Orbital fractures. UpToDate [serial online]. September 2006;Accessed September 14, 2007. Available at www.UpToDate.com.
Schwab RA, Genners K, Robinson WA. Clinical predictors of mandibular fractures. Am J Emerg Med. May 1998;16(3):304-5. [Medline].
Tesini DA, Soporowski NJ. Epidemiology of orofacial sports-related injuries. Dent Clin North Am. Jan 2000;44(1):1-18, v. [Medline].
Baker SM, Hurwitz JJ. Sports and industrial ophthalmology: management of orbital and ocular adnexal trauma. Ophthalmol Clin North Am. 1999;12:435-55.
Christensen GR. Eye injuries in sports: evaluation, management, and prevention. In: Mellion MB, Walsh WM, Shelton GL, eds. The Team Physician's Handbook. 2nd ed. Philadelphia, Pa: Hanley & Belfus, Inc; 1997:407-25.
Dominguez S. Maxillofacial trauma. In: Markovchick VJ, Pons PT, eds. Emergency Medicine Secrets. 2nd ed. Philadelphia, Pa: Hanley & Belfus, Inc; 1999:404-7.
Ellis E 3rd, Scott K. Assessment of patients with facial fractures. Emerg Med Clin North Am. Aug 2000;18(3):411-48, vi. [Medline].
Hendler BH. Maxillofacial Trauma. In: Rosen P, Barken R, eds. Emergency Medicine Concepts and Clinical Practice. 4th ed. St. Louis, Mo: Mosby-Year Book; 1998:1098-103.
Kaufman BR, Heckler FR. Sports-related facial injuries. Clin Sports Med. Jul 1997;16(3):543-62. [Medline].
Thomas SH. Maxillofacial injuries. In: Harwood-Nuss AL, ed. The Clinical Practice of Emergency Medicine. Philadelphia, Pa: Lippincott Williams & Wilkins; 1996:408-18.
Tu HK, Davis LF, Nique TA. Maxillofacial injuries. In: The Team Physician's Handbook. 2nd ed. Philadelphia, Pa: Hanley & Belfus, Inc; 1997:426-37.
maxillofacial fractures, tripod fractures, tetrapod fractures, blow-in fractures, blow-out fractures, blow out fractures, broken jaw, broken cheek, broken nose, Le Fort fracture, LeFort fracture, face fracture, nasal fracture, nasal bone fracture, orbital fracture, orbital floor fracture, orbital wall fracture
Timothy J Rupp, MD, FACEP, Associate Medical Director, Physicians Emergency Care Associates, Methodist Health System, Dallas, Texas; Staff Physician, Innovative Emergency Medicine, Frisco, Texas; Staff Physician, Department of Emergency Medicine, Children's Medical Center of Dallas, Dallas, Texas
Timothy J Rupp, MD, FACEP is a member of the following medical societies: American College of Emergency Physicians, American Medical Association, Gay and Lesbian Medical Association, Society for Academic Emergency Medicine, and Texas Medical Association
Disclosure: Nothing to disclose.
Steven Karageanes, DO, Director, Primary Care Sports Medicine Fellowship, Director, Sports Medicine Education, Center for Orthopedics and Neuroscience; Department of Medical Education, Oakwood Healthcare System
Steven Karageanes, DO is a member of the following medical societies: American Medical Association, American Osteopathic Association, and Michigan State Medical Society
Disclosure: Nothing to disclose.
Gerard A Malanga, MD, Founder and Director, New Jersey Sports Medicine Institute; Director of Pain Management, Overlook Hospital; Director of Sports Medicine, Sports Medicine Fellowship Director, Mountainside Hospital; Clinical Chief, Rehabilitation Medicine and Electrodiagnosis, St Michael's Medical Center; Medical Director, Consultant, Horizon Healthcare Worker's Compensation Services, Blue Cross and Blue Shield Worker's Compensation
Gerard A Malanga, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Physical Medicine and Rehabilitation, American College of Sports Medicine, North American Spine Society, and Physiatric Association of Spine, Sports and Occupational Rehabilitation
Disclosure: Nothing to disclose.
Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.
Henry T Goitz, MD, Chief, Sports Medicine, Associate Professor, Department of Orthopaedic Surgery, Medical College of Ohio
Henry T Goitz, MD is a member of the following medical societies: American Academy of Orthopaedic Surgeons and American Orthopaedic Society for Sports Medicine
Disclosure: Nothing to disclose.
Jon B Whitehurst, MD, Clinical Instructor of Surgery, University of Illinois College of Medicine; Partner and Executive Board Member, Rockford Orthopedic Associates; Orthopedic Chairman, Rockford Memorial Hospital
Jon B Whitehurst, MD is a member of the following medical societies: American Academy of Orthopaedic Surgeons, American Orthopaedic Society for Sports Medicine, and Arthroscopy Association of North America
Disclosure: Nothing to disclose.
Craig C Young, MD, Professor, Departments of Orthopedic Surgery and Community and Family Medicine, Medical Director of Sports Medicine, Sports Medicine Fellowship Director, Medical College of Wisconsin
Craig C Young, MD is a member of the following medical societies: American Academy of Family Physicians, American College of Sports Medicine, American Medical Society for Sports Medicine, Phi Beta Kappa, and Wilderness Medical Society
Disclosure: Nothing to disclose.
© 1994-
by Medscape.
All Rights Reserved
(http://www.medscape.com/public/copyright)